Log in

Relevant bibliographies by topics / Myalgia and maculo papular eruption

Contents

Journal articles

Academic literature on the topic 'Myalgia and maculo papular eruption'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Myalgia and maculo papular eruption.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Myalgia and maculo papular eruption"

1

Srinivas, G., D.V. Ramanjaneyulu, E. Muralinath, et al. "An Essential Parameters of Parvo Virus Include Patho Physiology, Histo Pathology, Diagnosis, Differential Diagnosis, Treatment and Prognosis." Journal of Research and Reviews in Nursing Science and Education 2, no. 2 (2025): 11–17. https://doi.org/10.5281/zenodo.15541791.

Full text

Abstract:

<em>One virus that only affects people is parvovirus B19. The fifth illness, also known as erythema infectious or slapped cheek syndrome, is known to be caused by it. It primarily affects young children, though it can sometimes affect adults. In addition, it may result in Poly arthropathy, popular-purpuric gloves and socks syndrome (PPGSS) in young people, certain anemias, hydrops fetalis, particularly in pregnant women, and an aplastic crisis. Viral transmission occurs through both respiratory secretions and blood products. The virus can infect a pregnant woman and then infect her unborn chil

APA, Harvard, Vancouver, ISO, and other styles

2

Sultana, Abida, Mohammed Saiful Islam Bhuiyan, and Md Mostaque Mahmud. "Pattern of Adverse Cutaneous Drug Reactions (ACDR) to Systemic Drugs." Bangladesh Medical Journal 47, no. 3 (2019): 32–36. http://dx.doi.org/10.3329/bmj.v47i3.43496.

Full text

Abstract:

Adverse cutaneous drug reaction (ACDR) is a common issue in dermatology practice and it is crucial for every medical practitioner to remain updated of its pattern. It was a hospital based crosssectional observational study, conducted over 130 patients with adverse cutaneous drug reactionin the outpatient department of dermatology of Bangabandhu Sheikh Mujib Medical University (BSMMU). Majority of reaction was developed within one week of taking drug. Fixed drug eruption (FDE) was present in 18.5% cases followed by maculo-papular, Stevenson-Johnson-Syndrome-Toxic epidermal necrolysis (SJS- TEN)

APA, Harvard, Vancouver, ISO, and other styles

3

Khondker, Lubna, Md Shirajul Islam Khan, and Abu Reza Sayem Ahamed. "Dermatological Manifestations of COVID-19 Patients." International Journal of Advanced Multidisciplinary Research and Studies 4, no. 3 (2024): 186–90. http://dx.doi.org/10.62225/2583049x.2024.4.3.2762.

Full text

Abstract:

Background: COVID-19 is a highly contagious respiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was first identified in China, in December 2019. Almost 10% of the patients develop dermatological manifestations before the onset of respiratory illness, with cutaneous signs that can appear from before to several days after the diagnosis of COVID-19. We believe that the dermatologist can play an important role through early recognition of skin lesions suggestive of COVID-19, particularly in asymptomatic infections where this recognition could direct

APA, Harvard, Vancouver, ISO, and other styles

4

Bhuptani, Neela, Priyanka Sondarva, Dipti Patel, and Tejashwani . "Myriad cutaneous presentation of chikungunya fever during recent epidemic in Gujarat: a case study of 124 cases." International Journal of Research in Dermatology 4, no. 2 (2018): 215. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20181822.

Full text

Abstract:

<p class="abstract"><strong>Background:</strong> Chikungunya fever (CKG) epidemic had been recently re-emerged in Gujarat affecting large population. It is an acute viral infection caused by Togavirus, transmitted by <em>Aedes</em> mosquitos, can present with abrupt onset of fever, severe arthralgia, constitutional symptoms and cutaneous manifestations. We have reviewed cutaneous manifestations of CKG during recent epidemic (July-October 2017). The object of the study was to determine incidence of various cutaneous manifestations of Chikungunya fever.</p>&lt

APA, Harvard, Vancouver, ISO, and other styles

5

Manzini, Thandekile C., Bernadett I. Gosnell, Melanie-Anne A. John, and Mahomed Y. S. Moosa. "Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome." Southern African Journal of Infectious Diseases 31, no. 4 (2016): 119–21. http://dx.doi.org/10.4102/sajid.v31i4.75.

Full text

Abstract:

Background: Non-nucleoside reverse transcriptase inhibitors (NNRTI) are recommended as part of first-line treatment by the World Health Organisation (WHO) for antiretroviral treatment (ART) naïve subjects. Due to reports of cross-toxicity between nevirapine (NVP) and efavirenz (EFV), there is reluctance to substitute EFV for NVP when serious toxicity occurs. In such cases lopinavir/ritonavir (LPV/r) remains the only alternative. We report on our experience of patients with Stevens-Johnson Syndrome (SJS) secondary to NVP who were challenged with EFV under careful supervision.Methods: A retrospe

APA, Harvard, Vancouver, ISO, and other styles

6

Miller, Aaron, Zeynep Kosaloglu-Yalcin, Luise Westernberg, et al. "A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer." Journal of Clinical Oncology 39, no. 15_suppl (2021): 2615. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2615.

Full text

Abstract:

2615 Background: Neoantigens (NeoAg) are key targets for personalized immunotherapy but efficient methods for their systematic identification and therapeutic targeting remain elusive. We developed a methodology to reliably identify and verify somatic alteration-derived neoantigens based on natural T cell responses against them which formed the basis of an individualized therapeutic vaccine strategy. Methods: This is a phase Ib study to assess the immunogenicity, safety and early clinical activity of personalized synthetic long peptides (PSLP) cancer vaccines in combination with pembrolizumab f

APA, Harvard, Vancouver, ISO, and other styles

7

Hubbard, Joleen M., Tyler J. Zemla, Rondell P. Graham, et al. "PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 3595. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3595.

Full text

Abstract:

3595 Background: PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine containing 12 immunogenic epitopes derived from 7 tumor-specific antigens frequently expressed in patients with mCRC. Following early evidence of clinical activity of PolyPEPI1018 in first-line MSS mCRC, here we report the results of a phase Ib study of PolyPEPI1018 vaccine plus trifluridine/tipiracil (TAS-102) in late-stage mCRC patients. Methods: Patients with MSS mCRC who have progressed on ≤2 lines of prior chemotherapy regimen for mCRC received PolyPEPI1018 subcutaneously on days 1 and 15 and TAS-102 orally twice dai

APA, Harvard, Vancouver, ISO, and other styles

8

Sun, Clare C., Pia Nierman, Inhye E. Ahn, et al. "Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)." Blood 132, Supplement 1 (2018): 4424. http://dx.doi.org/10.1182/blood-2018-99-110395.

Full text

Abstract:

Abstract Background: Bruton tyrosine kinase (BTK) is a critical component of B-cell receptor signaling and a validated target for CLL. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor, which has shown promising efficacy and safety in patients with CLL, including high-risk patients. We present preliminary efficacy, safety, and pharmacodynamic results from an ongoing single-center, open-label, phase 2 study of acalabrutinib monotherapy in patients with R/R and high-risk, TN CLL. Methods: Patients with R/R or high-risk (chromosome 17p deletion [del17p] or mutation in TP53 or NO

APA, Harvard, Vancouver, ISO, and other styles

9

Bouaziz, Imen, Rim Atheymen, Khadija Sellami, et al. "Lactulose induced maculo-papular eruption with positive rechallenge: unusual reaction to this medication*." Therapies, December 2024. https://doi.org/10.1016/j.therap.2024.12.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chouchana, Margot, Sylvine Pinel, Hester Colboc, et al. "Donepezil as a safe alternative treatment after maculo‐papular eruption related to rivastigmine in Lewy body disease: a case report and pharmacovigilance data." Psychogeriatrics, July 25, 2024. http://dx.doi.org/10.1111/psyg.13166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!